CHAIN Biotech

CHAIN Biotech is a private, pre-clinical stage biotech leveraging its proprietary Clostridium Assisted Drug Delivery (CADD™) platform to create orally administered vaccines and immuno-therapies. The platform utilizes engineered, non-pathogenic Clostridium butyricum spores to deliver therapeutic payloads directly to the lower GI tract, aiming to overcome traditional oral delivery challenges. The company is initially focused on anti-infective and anti-cancer vaccines, has secured seed funding, and is building strategic collaborations, such as one with the German Cancer Research Center (DKFZ), to advance its pipeline.

Clostridium Assisted Drug Delivery (CADD™) platform: Uses engineered, non-pathogenic Clostridium butyricum spores for oral delivery and in situ production of therapeutic payloads (e.g., vaccines, immuno-therapies) in the lower gastrointestinal tract.

CHAIN operates in the competitive microbiome therapeutics and oral vaccine delivery space, competing with other companies engineering bacteria (e.g., Synlogic, Vedanta Biosciences) and developing novel oral delivery technologies. Its specific focus on Clostridium spores and lower GI targeting is a key differentiator, but it must demonstrate superior efficacy, safety, and manufacturability to gain market share against both emerging platforms and established pharmaceutical companies investing in these areas.